Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hereditary angieoedema
Biotech
Intellia showcases durability of one-and-done HAE option
The future of hereditary angiodema treatment seems to be coming down to how many shots it takes to reduce attacks.
Annalee Armstrong
Jun 2, 2024 8:00am
Ionis reveals oasis for HAE patients as RNA med reduces attacks
May 31, 2024 10:40am
Pharvaris oral hereditary angioedema med cuts attacks in phase 2
Dec 6, 2023 10:18am
Pharvaris runs tox test to reverse clinical hold for HAE asset
Jan 9, 2023 10:42am
Catabasis Pharmaceuticals no more: Meet Astria Therapeutics
Sep 8, 2021 9:00am
KalVista hit with a clinical hold on 2nd asset
Apr 20, 2021 8:05am
